Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies

Zacks identifies Veracyte, Globus Medical and UFP Technologies as potential beneficiaries of accelerating GenAI adoption in medical instruments, with the healthcare AI market projected to grow at a 43.9% CAGR from 2026-2034. Consensus forecasts call for 2026 EPS growth of 8.4% for Veracyte, 25.4% for Globus Medical and 8.0% for UFP, alongside revenue growth of 14.4%, 8.8% and 9.1%, respectively. The industry ranks in the top 40% of Zacks sectors but has underperformed over the past year, falling 2.5% versus a 19.0% S&P 500 gain, while its 25.97x forward P/E remains above both the sector and index.

Analysis

This is not a standalone AI catalyst: monetization will be determined by reimbursement, clinical validation and regulatory clearance rather than adoption rhetoric. VCYT has the cleanest potential operating leverage if molecular-test volume growth converts into higher lab utilization; however, its valuation support depends on evidence that new indications expand reimbursed testing rather than merely shifting share within existing diagnostic workflows. The key 1-3 month watch item is whether management raises test-volume or gross-margin guidance, not incremental AI product language.

GMED's earnings sensitivity is more tangible but indirect: workflow, imaging and surgical-planning capabilities can improve pull-through of its implant and enabling-technology portfolio, while its larger installed base creates data advantages over smaller spine competitors. The offset is integration execution; a revenue-synergy miss or sustained procedure disruption would make the market revalue GMED as a serial acquirer rather than a differentiated platform. UFPT is a second-order beneficiary of procedure growth and medical-device outsourcing, but acquired-revenue quality, customer concentration and integration costs matter more to near-term EPS than GenAI.

The more actionable sector implication is that higher regulatory standards favor scaled incumbents with clinical, quality-system and post-market-surveillance infrastructure, including DHR, BSX and MDT. That creates a barbell: premium diagnostics exposure via VCYT plus diversified large-cap medtech, while avoiding speculative imaging/AI names such as NNOX until reimbursement and utilization data demonstrate recurring economics. Consensus may be too quick to assign software-like multiples to a category where compliance expense and liability risk can absorb much of the productivity gain over the next 6-18 months.

Key Decisions for Investors

• Initiate a 3-6 month long VCYT / short NNOX relative-value position: favor reimbursed diagnostic volume and lab-utilization economics over a higher-beta AI-imaging narrative. Reassess if VCYT fails to deliver accelerating test-volume growth or if NNOX secures material reimbursement/utilization evidence; target 15-20% relative upside with a 7-10% relative stop.
• Accumulate GMED on post-earnings or integration-related weakness for a 6-12 month horizon, conditional on stable procedure growth and maintained margin guidance. Risk/reward improves only if synergy realization offsets acquisition dilution; exit on a revenue-guide cut or evidence that international growth decelerates materially.
• Use UFPT as an outsourcing-cycle watch rather than an AI trade: add only after confirming organic growth versus acquisition contribution and gross-margin progression in the next report. A short-term premium is vulnerable if deal costs or customer-program timing dilute earnings conversion.
• Pair long BSX or DHR against a basket of smaller unprofitable AI-healthcare names over 6-18 months. Larger platforms are better positioned to absorb EU/FDA compliance costs and acquire validated assets; the thesis is falsified by a regulatory framework that materially lowers clearance burdens or by clear reimbursement-led scale at smaller entrants.
• Do not chase the immediate publication-driven move. Set alerts around earnings guidance, reimbursement decisions and FDA GenAI-device rulemaking; these are the events capable of changing cash-flow estimates and multiples, whereas analyst-rank changes alone are unlikely to sustain alpha.